Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice

Lei Wang, Zi Wang, Jiandang Shi, Qian Jiang, Hong Wang, Li Xu, Hao DiInternational Journal of Molecular Medicine 2018 · DOI

Abstract

The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to protect various cell types against apoptosis by interacting with the apolipoprotein E receptor 2 (ApoER2). This study investigated the association between PCSK9/ApoER2 signaling and neuronal apoptosis following middle cerebral artery occlusion (MCAO) injury in hyperlipidemic mice. C57BL/6 mice fed a high-fat diet (HFD) were subjected to MCAO, followed by cortical injection of a lentiviral vector harboring short-hairpin RNA (shRNA) targeting PCSK9. Results demonstrated that hyperlipidemia significantly upregulates PCSK9 expression. Ischemia-induced increases in PCSK9 and ApoER2 levels, as well as neuronal apoptosis, were significantly attenuated by PCSK9 shRNA treatment. These findings suggest that the PCSK9/ApoER2 axis is a potential therapeutic target for stroke in hyperlipidemic patients.

Introduction

Ischemic stroke is a leading cause of disability and death worldwide, with hyperlipidemia serving as a major modifiable risk factor. While PCSK9 is primarily known for its role in regulating hepatic low-density lipoprotein (LDL) receptors, its function in the central nervous system is increasingly recognized. Previous research has suggested that PCSK9 may influence neuronal development and cell death, though its interaction with brain receptors like ApoER2 under pathological conditions remains controversial. This study aimed to determine if PCSK9 exacerbates brain damage during stroke in hyperlipidemic conditions and to identify the underlying molecular mechanisms.

Materials and Methods

C57BL/6 mice were fed a high-fat diet (HFD) for six weeks to induce hyperlipidemia, while control mice received a normal-fat diet (NFD). Focal ischemic stroke was simulated using the Middle Cerebral Artery Occlusion (MCAO) model. To inhibit PCSK9, researchers utilized a lentiviral vector carrying shRNA, delivered via stereotaxic injection into the cerebral cortex. Analysis included RT-qPCR for mRNA quantification, Western blotting and Immunohistochemistry (IHC) for protein levels, and TUNEL assays to detect neuronal apoptosis.

Results

Hyperlipidemia and Baseline PCSK9 Elevation

Dietary induction of hyperlipidemia resulted in significantly higher serum LDL-C levels. Notably, HFD mice also exhibited a corresponding increase in PCSK9 mRNA and protein expression within the hippocampus and cortex compared to NFD controls, establishing a baseline of neuro-vulnerability prior to ischemic injury.

Lipid profiles and baseline PCSK9 expression in NFD and HFD mice.

The Stroke-PCSK9 Feedback Loop

Ischemic injury further exacerbated the expression of PCSK9 and ApoER2 in the brain. Western blot analysis confirmed that MCAO significantly increased PCSK9 levels in both the hippocampus and cortex of hyperlipidemic mice compared to sham-operated controls.

Western blot analysis showing increased PCSK9 expression in the hippocampus and cortex following MCAO injury.

Neuroprotection via PCSK9 Silencing

Silencing PCSK9 with shRNA successfully reduced ApoER2 protein levels, confirming a functional link between these two pathways during ischemic injury. This molecular intervention led to markedly less histological injury—characterized by reduced vacuolization and neutrophil infiltration—and a significant decrease in the ratio of apoptotic cells in the ischemic penumbra.

Discussion

This study highlights that in a pathological state (stroke combined with high cholesterol), PCSK9 levels are directly correlated with ApoER2 levels. This contrasts with some findings in healthy adult models and suggests that the brain's response to injury in a hyperlipidemic environment is inherently pro-apoptotic. By "knocking down" PCSK9, the researchers were able to downregulate the ApoER2 signaling pathway and provide significant neuroprotection.

Conclusion

The data demonstrate that PCSK9 shRNA-mediated anti-apoptotic effects following MCAO in hyperlipidemic mice are associated with ApoER2 downregulation. This identifies the PCSK9/ApoER2 axis as a potential new therapeutic target for stroke treatment, particularly for patients with comorbid hyperlipidemia.

Summary updated

Abstract

The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) protects a variety of cell types against neuronal apoptosis by binding to apolipoprotein E receptor 2 (ApoER2). The present study aimed to determine the association between PCSK9/ApoER2 signaling and neuronal apoptosis following middle cerebral artery occlusion (MCAO) injury in hyperlipidemic mice. For this purpose, C57BL/6 mice fed with a high‑fat diet (HFD) for 6 weeks were exposed to MCAO. Subsequently, PCSK9 was inhibited by a lentiviral vector harboring short‑hairpin RNA (shRNA) targeting PCSK9, which was stereotaxically injected into the cerebral cortex of mice. At 48 h post‑ischemia, hematoxylin‑eosin staining and a terminal deoxynucleotidyl transferase dUTP nick end labeling assay were performed to determine cerebral tissue injury and apoptosis. PCSK9 and ApoER2 expression levels were assessed by reverse transcription‑quantitative polymerase chain reaction, immunohistochemistry and western blotting. The results indicated that hyperlipidemia and increased PCSK9 expression were evident in HFD mice. Cerebral histological injury and neuronal apoptosis, as well as PCSK9 and ApoER2 levels, which were increased upon ischemia in hyperlipidemic mice, were attenuated by PCSK9 shRNA treatment. These protective effects of PCSK9 shRNA interference were associated with decreased neuronal apoptosis and a reduced level of ApoER2 expression in the hippocampus and cortex. The data of the present study demonstrated that the PCSK9 shRNA‑mediated anti‑apoptotic effect induced by MCAO in hyperlipidemic mice is associated with ApoER2 downregulation, which may be a potential new therapy for stroke treatment in patients with hyperlipidemia.
BibTeX
@article{wang2018inhibition,
  author = {Lei Wang and Zi Wang and Jiandang Shi and Qian Jiang and Hong Wang and Li Xu and Hao Di},
  title = {{Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice}},
  journal = {International Journal of Molecular Medicine},
  year = {2018},
  doi = {10.3892/ijmm.2018.3797},
}
Figure